Between December 2021 and December 2024, KCE was entrusted with the coordination of the "Task Force Therapeutics’ (TF-Tx)". The role of this Task Force was to analyse available scientific data in order to provide the authorities with the advice they needed to make decisions on the purchase of drugs against (emerging) viral diseases.
Initially, the Task Force's activities focused solely on drugs against COVID-19. Its advice on this subject is available on the COVID-19 page.
Later on, new developments led the Task Force to broaden its activities to encompass other viral diseases. The reports and advisory documents published in this context are listed below.
- Advice regarding the purchase of tecovirimat for the treatment of monkeypox patients in Belgium (31/5/2022)
- Tecovirimat for Mpox – updated stockpiling advice (02/10/2024)
- Baloxavir for strategic stockpile against influenza pandemic (02/10/2024)
- Clinical effectiveness of Brincidofovir against smallpox (03/04/203)
- Clinical effectiveness of Favipiravir against Ebola virus disease (03/04/203)
- Clinical effectiveness of Ribavirin against Lassa Fever and Crimean-Congo Haemorraghic Fever (03/04/2023)
- Advice regarding the purchase of oseltamivir for the constitution of a strategic stockpile in case of influenza pandemic (7/11/2022)
CONTACT
ANNUAL REPORT
